Las Vegas, NV -- (SBWIRE) -- 12/31/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more. EquityObserver.com issues a special report on the following stocks:AirMedia Group Inc (ADR)(NASDAQ:AMCN),RadioShack Corporation(NYSE:RSH),Berkshire Hathaway Inc.(NYSE:BRK.B),Oramed Pharmaceuticals, Inc.(NASDAQ:ORMP)
AirMedia Group Inc (ADR)(NASDAQ:AMCN)managed to keep its gain at 1.06% on above-normal volume of 2.09Mshares. The stock settled at $1.90, after floating in a range of $1.85 - 2.04. Its latest price has reached market capitalization of $116.01M. Its 52-week range has been $1.50 - 3.20. AirMedia Group Inc is a holding company.
How Should Investors Trade AMCN Now?Don’t Miss out a Special Trend Analysis
RadioShack Corporation(NYSE:RSH)trading on a volume of 1.96Mshares, higher than its standard daily volume. Shares have been closed at $2.67. Over the last twelve months, the stock has gained25.94% and faced a worst price of $2.05.RadioShack Corporation (RadioShack) is engaged in the retail sale of consumer electronics goods and services through its RadioShack store chain.
Is RSH a Solid Investment at These Levels?Read This Report for Details
Berkshire Hathaway Inc.(NYSE:BRK.B)is up at $118.04 on below- normal volume of 1.94Mshares during the last trading day. The stock has its 12-month range $88.11 - 119.30. Its Intraday range is $117.75 - 118.56.Berkshire Hathaway Inc. (Berkshire) is a holding company owning subsidiaries engaged in a number of diverse business activities.
How Should Investors Trade BRK.B Now?Don’t Miss out a Special Trend Analysis
In the last trading day, Oramed Pharmaceuticals, Inc.(NASDAQ:ORMP)is on high volume, trading at a volume of versus its average daily volume ratio 1.94M/372,271.00 shares. At $15.06, the stock has attained market capitalization of 118.99MOramed Pharmaceuticals Inc. is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides.
Will Investors Buy ORMP After Reading This News?Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)